… ProQR Receives Fast Track Designation from FDA for QR-1123 … Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We look forward to beginning enrollment in the Phase …
… ProQR spins out Amylon Therapeutics as a privately-held … on central nervous system (CNS) therapeutics Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, … and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop …
… ProQR Prices Approximately $20 Million Underwritten Public … LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … $3.25 per share. All of the shares are being offered by ProQR. In addition, in the public offering, ProQR has …
… ProQR Doses First Patient in Phase 1/2 STELLAR Trial of … of the first studies of its kind exploring the impact of ProQR’s RNA therapies on patients with Usher syndrome due to … mutation. The STELLAR trial will explore whether QR-421a (ProQR’s RNA therapy) can slow disease progression or even …
Top-line data now expected to be announced in Q1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
… ProQR Receives Orphan Drug Designation from EMA for Drug … QR-313 for Dystrophic Epidermolysis Bullosa Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis …
LEIDEN, the Netherlands, Sept. 14, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that PQ-010-002 is open for enrollment.
… ProQR Announces Presentation on QR-421a Program in … and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … delivered by Dr. Aniz Girach, MD, chief medical officer of ProQR, on QR-421a for Usher Syndrome during the USH2019 …